Trial reportScientific reports2021
Development of a scale for early prediction of refractory Mycoplasma pneumoniae pneumonia in hospitalized children.
Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 52 citations in OpenAlex.
- Efficacy of Gamma Globulin Combined with Azithromycin Sequential Therapy in the Treatment of RMPP and Its Effect on Th1/Th2 Cytokine Levels.Computational and mathematical methods in medicine · 2022Trial
- Neutrophils promote endothelial cell activation in pediatric Mycoplasma pneumoniae pneumonia.JCI insight · 2026Article
- Application of Clinical Indicators in the Early Prediction of RefractoryClinical pediatrics · 2026Article
- Development and validation of a multivariate predictive model for the risk of refractory mycoplasma pneumoniae pneumonia in children based on quantitative computed tomography features.Translational pediatrics · 2026Article
- Independent risk factors and predictive model for high hospitalization costs in children with Mycoplasma pneumoniae pneumonia.BMC pediatrics · 2026Article
- Epidemiological characteristics of Mycoplasma pneumoniae in hospitalized children before during and after the COVID-19 pandemic in xi'an China.Scientific reports · 2026Article
- Prediction models for refractoryFrontiers in pediatrics · 2026Article
- Doxycycline treatment for drug-resistantFrontiers in medicine · 2026Article
- Post-COVID-19 disruption of the respiratory microbiome modulatesEmerging microbes & infections · 2025Article
- Epidemiology and clinical profiles of neonates withTranslational pediatrics · 2025Article
- Clinical characteristics and outcomes of macrolide-resistantTranslational pediatrics · 2025Article
- Combining circ_0054633 and clinical features to predict refractory Mycoplasma pneumoniae pneumonia in children.Scientific reports · 2025Article
- Clinical features associated with macrolides resistance of Mycoplasma pneumoniae pneumonia in children: a single-center analysis.BMC infectious diseases · 2025Article
- Volume ratio of pulmonary lesions as a novel indicator for predicting the occurrence of plastic bronchitis in children with Mycoplasma pneumoniae pneumonia.European journal of pediatrics · 2025Article
- Predictive value of an early comprehensive assessment model for refractory mycoplasma pneumoniae pneumonia and internal validation.BMC infectious diseases · 2025Article
- Significance of respiratory virus coinfection in children with Mycoplasma pneumoniae pneumonia.BMC pulmonary medicine · 2024Article
- Predicting the severity of mycoplasma pneumoniae pneumonia in pediatric and adult patients: a multicenter study.Scientific reports · 2024Article
- Comparative observation between Roxithromycin and Azithromycin sequential therapy in the treatment of Mycoplasma pneumoniae Pneumonia in Children.Pakistan journal of medical sciences · 2024Article
- Construction of a nomogram for early diagnosis of refractoryTranslational pediatrics · 2024Article
- Model based on the automated AI-driven CT quantification is effective for the diagnosis of refractory Mycoplasma pneumoniae pneumonia.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Now there is no clinical scale for early prediction of refractory Mycoplasma pneumoniae pneumonia (RMPP). The aim of this study is to identify indicators and develop an early predictive scale for RMPP in hospitalized children. First we conducted a retrospective cohort study of children with M. pneumoniae pneumonia admitted to Children's Hospital of Nanjing Medical University, China in 2016. Children were divided into two groups, according to whether their pneumonia were refractory and the results were used to develop an early predictive scale. Second we conducted a prospective study to validate the predictive scale for RMPP in children in 2018. 618 children were included in the retrospective study, of which 73 with RMPP. Six prognostic indicators were identified and included in the prognostic assessment scale. The sensitivity of the prognostic assessment scale was 74.0% (54/73), and the specificity was 88.3% (481/545) in the retrospective study. 944 children were included in the prospective cohort, including 92 with RMPP, the sensitivity of the prognostic assessment scale was 78.3% (72/92) and the specificity was 86.2% (734/852). The prognostic assessment scale for RMPP has high diagnostic accuracy and is suitable for use in standard clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.